Characterization of Nanoparticle based formulations: Dissolution Studies with NanoDis
Agilent Technologies: Characterization of Nanoparticle based formulations: Dissolution Studies with NanoDis
Nanocarriers and nanoformulations have been investigated in pharmaceutical research for many years.
These nanomedicines offer multiple solutions, from protecting the active pharmaceutical ingredient from biological environments to enhancing the bioavailability and stability of the drug at the site of action. Although nanomedical research is in the spotlight and more commercialized nanoformulations are on the market, there are no standardized procedures or regulations for the assessment of the quality and safety profiles of such products. In this study, the release profile of poly (lactic co-glycolic) (PLGA) nanocapsules loaded with all-trans retinoic acid (RA) was characterized using an innovative sample and separation setup, the Agilent NanoDis system. The results were compared to the release profile measured with a dialysis technique.
Presenter: Emre Türeli, PhD (Chief Scientific Officer, MyBiotech, Germany)
Dr.EmreTüreli holds a PhD degree in Pharmaceutical Technology from Johannes Gutenberg University in Mainz, Germany. Dr. Türeli has more than 20 years of international research and development experience, as well as executive management experience in the pharmaceutical industry. His expertise is in drug delivery systems, nanoparticle development, and production method development in a pharmaceutical industrial environment.
Presenter: Manu Grover (Business Development Manager – Pharma Markets, Agilent Technologies, Inc.)
Manu Grover holds a postgraduate degree in Pharmacy from Manipal Academy, India. He has more than 21 years of chromatography experience and has worked in pharmaceuticals to support IND, NDA, and ANDA filings incompanies such as Dr. Reddy's, Panacea Biotec, and Ozone Pharmaceuticals. During his professional journey, he has developed and validated analytical methods on HPLC, GC, particle sizing, DSC, pXRD, and LC/MS instruments, as well as successfully filing multiple analytical dossiers in U.S./EU markets. In his current role, he works closely with the Agilent sales team, regulators, and pharmaceutical scientists. He shares market updates, trends, and expertise related tothe Agilent portfolio of columns and supplies.